{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T05:31:28Z","timestamp":1769923888782,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["ZIA-DC00008"],"award-info":[{"award-number":["ZIA-DC00008"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngologic Clinics of North America"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.otc.2021.05.002","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T01:57:57Z","timestamp":1622858277000},"page":"769-777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Biologics for the Treatment of Recurrent Respiratory Papillomatosis"],"prefix":"10.1016","volume":"54","author":[{"given":"Clint T.","family":"Allen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.otc.2021.05.002_bib1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.otc.2019.03.011","article-title":"Update on recurrent respiratory papillomatosis","volume":"52","author":"Derkay","year":"2019","journal-title":"Otolaryngol Clin North Am"},{"issue":"38","key":"10.1016\/j.otc.2021.05.002_bib2","doi-asserted-by":"crossref","first-page":"19055","DOI":"10.1073\/pnas.1906184116","article-title":"Homozygous NLRP1 gain-of-function mutation in siblings with a syndromic form of recurrent respiratory papillomatosis","volume":"116","author":"Drutman","year":"2019","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.otc.2021.05.002_bib3","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/0194599818774754","article-title":"Development of human-derived cell culture lines for recurrent respiratory papillomatosis","volume":"159","author":"Attra","year":"2018","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"10.1016\/j.otc.2021.05.002_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/0003489414546400","article-title":"Xenograft model for therapeutic drug testing in recurrent respiratory papillomatosis","volume":"124","author":"Ahn","year":"2015","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"3","key":"10.1016\/j.otc.2021.05.002_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3851\/IMP2612","article-title":"Targeting human papillomavirus genome replication for antiviral drug discovery","volume":"18","author":"Archambault","year":"2013","journal-title":"Antivir Ther"},{"issue":"4","key":"10.1016\/j.otc.2021.05.002_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-126-4-199702150-00002","volume":"126","year":"1997","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.otc.2021.05.002_bib7","first-page":"523","article-title":"Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines","volume":"10","author":"Andrei","year":"1998","journal-title":"Oncol Res"},{"issue":"2","key":"10.1016\/j.otc.2021.05.002_bib8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/jmv.1890450221","article-title":"Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine","volume":"45","author":"Van Cutsem","year":"1995","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.otc.2021.05.002_bib9","first-page":"CD005053","article-title":"Adjuvant antiviral therapy for recurrent respiratory papillomatosis","volume":"12","author":"Chadha","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.otc.2021.05.002_bib10","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/000348941112001001","article-title":"Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study","volume":"120","author":"Zeitels","year":"2011","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.otc.2021.05.002_bib11","doi-asserted-by":"crossref","first-page":"109706","DOI":"10.1016\/j.ijporl.2019.109706","article-title":"Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: A case report","volume":"128","author":"Hamdi","year":"2020","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.otc.2021.05.002_bib12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.12659\/AJCR.904416","article-title":"Systemic bevacizumab for recurrent respiratory papillomatosis: a single center experience of two cases","volume":"18","author":"Bedoya","year":"2017","journal-title":"Am J Case Rep"},{"issue":"10","key":"10.1016\/j.otc.2021.05.002_bib13","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/lary.26662","article-title":"Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey","volume":"127","author":"Best","year":"2017","journal-title":"Laryngoscope"},{"issue":"4","key":"10.1016\/j.otc.2021.05.002_bib14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/lary.27674","article-title":"Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children","volume":"129","author":"Carnevale","year":"2019","journal-title":"Laryngoscope"},{"issue":"5","key":"10.1016\/j.otc.2021.05.002_bib15","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3892\/ol.2014.2486","article-title":"Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis","volume":"8","author":"Mohr","year":"2014","journal-title":"Oncol Lett"},{"issue":"8","key":"10.1016\/j.otc.2021.05.002_bib16","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.otc.2021.05.002_bib17","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.19.02394","article-title":"Phase Ib\/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003","volume":"38","author":"Dudek","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.otc.2021.05.002_bib18","doi-asserted-by":"crossref","first-page":"e99114","DOI":"10.1371\/journal.pone.0099114","article-title":"Recurrent respiratory papillomatosis: HPV genotypes and risk of high-grade laryngeal neoplasia","volume":"9","author":"Omland","year":"2014","journal-title":"PLoS One"},{"issue":"Suppl 5","key":"10.1016\/j.otc.2021.05.002_bib19","doi-asserted-by":"crossref","first-page":"F34","DOI":"10.1016\/j.vaccine.2012.05.070","article-title":"Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis","volume":"30","author":"Gillison","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.otc.2021.05.002_bib20","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fimmu.2020.00336","article-title":"Altered monocyte and langerhans cell innate immunity in patients with recurrent respiratory papillomatosis (RRP)","volume":"11","author":"Israr","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.otc.2021.05.002_bib21","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1086\/381764","article-title":"Polymorphism of transporter associated with antigen presentation 1 as a potential determinant for severity of disease in recurrent respiratory papillomatosis caused by human papillomavirus types 6 and 11","volume":"189","author":"Vambutas","year":"2004","journal-title":"J\u00a0Infect Dis"},{"issue":"7","key":"10.1016\/j.otc.2021.05.002_bib22","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1158\/1078-0432.CCR-11-2941","article-title":"Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T\u00a0cells and PD-1\/PD-L1\/L2 expression","volume":"18","author":"Hatam","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.otc.2021.05.002_bib23","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.4049\/jimmunol.1004181","article-title":"Papillomavirus-specific CD4+ T\u00a0cells exhibit reduced STAT-5 signaling and altered cytokine profiles in patients with recurrent respiratory papillomatosis","volume":"186","author":"James","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"8","key":"10.1016\/j.otc.2021.05.002_bib24","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.humimm.2004.05.014","article-title":"HLA alleles, IFN-gamma responses to HPV-11 E6, and disease severity in patients with recurrent respiratory papillomatosis","volume":"65","author":"Bonagura","year":"2004","journal-title":"Hum Immunol"},{"issue":"1","key":"10.1016\/j.otc.2021.05.002_bib25","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1002\/lary.26847","article-title":"The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis","volume":"128","author":"Ahn","year":"2018","journal-title":"Laryngoscope"},{"key":"10.1016\/j.otc.2021.05.002_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijporl.2017.02.022","article-title":"PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis","volume":"95","author":"Liu","year":"2017","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"1","key":"10.1016\/j.otc.2021.05.002_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40425-019-0603-3","article-title":"Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis","volume":"7","author":"Allen","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"15_suppl","key":"10.1016\/j.otc.2021.05.002_bib28","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1200\/JCO.2019.37.15_suppl.2502","article-title":"A\u00a0phase II study of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal, and\/or pulmonary involvement","volume":"37","author":"Pai","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.otc.2021.05.002_bib29","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s00405-016-4085-3","article-title":"Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis","volume":"273","author":"Tjon Pian Gi","year":"2016","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"3","key":"10.1016\/j.otc.2021.05.002_bib30","doi-asserted-by":"crossref","first-page":"e0230065","DOI":"10.1371\/journal.pone.0230065","article-title":"The subjective well-being effect of public goods provided by village collectives: evidence from China","volume":"15","author":"Li","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.otc.2021.05.002_bib31","first-page":"363","article-title":"Safety and immunogenicity of a nonadjuvant human papillomavirus type 6 virus-like particle vaccine in recurrent respiratory papillomatosis","volume":"33","author":"Zhang","year":"2019","journal-title":"J\u00a0Voice"},{"issue":"2","key":"10.1016\/j.otc.2021.05.002_bib32","first-page":"208","article-title":"A\u00a0prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a National HPV Vaccination Program","volume":"217","author":"Novakovic","year":"2018","journal-title":"J\u00a0Infect Dis"},{"issue":"2","key":"10.1016\/j.otc.2021.05.002_bib33","first-page":"223","article-title":"The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma","volume":"29","author":"Young","year":"2015","journal-title":"J\u00a0Voice"},{"issue":"2","key":"10.1016\/j.otc.2021.05.002_bib34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/lary.27993","article-title":"Multi-year effect of human papillomavirus vaccination on recurrent respiratory papillomatosis","volume":"130","author":"Matsuzaki","year":"2020","journal-title":"Laryngoscope"},{"issue":"3","key":"10.1016\/j.otc.2021.05.002_bib35","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/coa.13076","article-title":"A\u00a0retrospective case-control analysis of the efficacy of Gardasil((R)) vaccination in 28 patients with recurrent respiratory papillomatosis of the larynx","volume":"43","author":"Milner","year":"2018","journal-title":"Clin Otolaryngol"},{"issue":"1","key":"10.1016\/j.otc.2021.05.002_bib36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12879-018-3260-0","article-title":"HPV vaccination as preventive approach for recurrent respiratory papillomatosis - a 22-year retrospective clinical analysis","volume":"18","author":"Mauz","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.otc.2021.05.002_bib37","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/0956462420920142","article-title":"Could the human papillomavirus vaccine prevent recurrence of ano-genital warts?: a systematic review and meta-analysis","volume":"31","author":"Husein-ElAhmed","year":"2020","journal-title":"Int J STD AIDS"},{"issue":"7","key":"10.1016\/j.otc.2021.05.002_bib38","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/infdis\/jiy616","article-title":"Therapeutic use of the human papillomavirus vaccine on recurrent respiratory papillomatosis: a systematic review and meta-analysis","volume":"219","author":"Rosenberg","year":"2019","journal-title":"J\u00a0Infect Dis"},{"issue":"6","key":"10.1016\/j.otc.2021.05.002_bib39","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/01.AOG.0000245786.86267.80","article-title":"Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer","volume":"108","author":"Hampl","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"19","key":"10.1016\/j.otc.2021.05.002_bib40","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.otc.2021.05.002_bib41","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1158\/1078-0432.CCR-15-2594","article-title":"Vaccination against Oncoproteins of HPV16 for noninvasive vulvar\/vaginal lesions: lesion clearance is related to the strength of the T-cell response","volume":"22","author":"van Poelgeest","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.otc.2021.05.002_bib42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00405-019-05351-6","article-title":"Experimental research on the therapeutic effect of MMR vaccine to juvenile-onset recurrent respiratory papillomatosis","volume":"276","author":"Wang","year":"2019","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"3","key":"10.1016\/j.otc.2021.05.002_bib43","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/hed.25477","article-title":"MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis","volume":"41","author":"Cabo Beltran","year":"2019","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.otc.2021.05.002_bib44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/vaccines8010056","article-title":"Immune therapy targeting E6\/E7 oncogenes of human paillomavirus type 6 (HPV-6) reduces or eliminates the need for surgical intervention in the treatment of HPV-6 associated recurrent respiratory papillomatosis","volume":"8","author":"Aggarwal","year":"2020","journal-title":"Vaccines (Basel)"}],"container-title":["Otolaryngologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666521000827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666521000827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T14:52:44Z","timestamp":1758466364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0030666521000827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0030666521000827"],"URL":"https:\/\/doi.org\/10.1016\/j.otc.2021.05.002","relation":{},"ISSN":["0030-6665"],"issn-type":[{"value":"0030-6665","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics for the Treatment of Recurrent Respiratory Papillomatosis","name":"articletitle","label":"Article Title"},{"value":"Otolaryngologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.otc.2021.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}